ExodusPoint Capital Management LP Sells 36,266 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

ExodusPoint Capital Management LP reduced its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Rating) by 63.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,528 shares of the company’s stock after selling 36,266 shares during the period. ExodusPoint Capital Management LP’s holdings in Xeris Biopharma were worth $32,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC raised its position in shares of Xeris Biopharma by 128.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 72,857 shares of the company’s stock valued at $114,000 after purchasing an additional 40,913 shares during the last quarter. Barclays PLC raised its position in shares of Xeris Biopharma by 105.3% in the 3rd quarter. Barclays PLC now owns 60,745 shares of the company’s stock valued at $95,000 after purchasing an additional 31,151 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $40,000. Deltec Asset Management LLC raised its position in shares of Xeris Biopharma by 32.5% in the 3rd quarter. Deltec Asset Management LLC now owns 537,926 shares of the company’s stock valued at $839,000 after purchasing an additional 131,926 shares during the last quarter. Finally, Bailard Inc. purchased a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $87,000. 0.12% of the stock is currently owned by institutional investors.

Xeris Biopharma Stock Performance

XERS opened at $1.45 on Monday. Xeris Biopharma Holdings, Inc. has a 12-month low of $0.97 and a 12-month high of $2.95. The company has a current ratio of 2.17, a quick ratio of 1.88 and a debt-to-equity ratio of 2.52. The firm has a market capitalization of $196.52 million and a PE ratio of -1.42. The firm has a 50 day moving average of $1.22 and a two-hundred day moving average of $1.41.

Analyst Upgrades and Downgrades

Separately, SVB Leerink decreased their price objective on shares of Xeris Biopharma from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, January 27th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $5.50.

About Xeris Biopharma

(Get Rating)

Xeris Biopharma Holdings, Inc is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing’s syndrome.